Disclosed herein, are compositions comprising one or more molecular guidance system (MGS) peptides and a cytotoxic agent. Also described herein, are methods of administering the compositions to patients with cancer.

Disclosed herein, are compositions comprising one or more molecular guidance system (MGS) peptides and a cytotoxic agent. Also described herein, are methods of administering the compositions to patients with cancer.

An oral delivery system based on in situ forming protein/polysaccharide coacervates is described herein. The system comprises an uncoacervated, dry homogenous mixture comprising a protein powder, a polysaccharide powder, and an active ingredient dispersed therein, wherein the polysaccharide powder has a Carr compressibility index greater than 25% to enable the protein and polysaccharide powders to form a protein/polysaccharide complex coacervate in situ upon immersion of the oral delivery system in a gastric fluid, thereby conferring gastric protection and/or modified release to the active ingredient.

An oral delivery system based on in situ forming protein/polysaccharide coacervates is described herein. The system comprises an uncoacervated, dry homogenous mixture comprising a protein powder, a polysaccharide powder, and an active ingredient dispersed therein, wherein the polysaccharide powder has a Carr compressibility index greater than 25% to enable the protein and polysaccharide powders to form a protein/polysaccharide complex coacervate in situ upon immersion of the oral delivery system in a gastric fluid, thereby conferring gastric protection and/or modified release to the active ingredient.

Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified lectins. Also disclosed are methods for making and using the compositions.

Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified lectins. Also disclosed are methods for making and using the compositions.

Methods for regulating multiple organs, multiple genes and multiple targets by using a polypeptide. The polypeptide includes the amino acid sequence of SEQ ID No. 1 and/or homology thereof. The polypeptide reveals the potency to regulate transcription of multiple genes and expression of multiple targets. Therefore, a composition having the polypeptide can be applied to regulate the expression of multiple targets in multiple organs of patients. Furthermore, the composition having the polypeptide can be applied in therapies of inflammation and inflammatory disorders, suppression of fatty liver disease progression, suppression of the diseases caused by fatty accumulation, prevention and therapy of muscular atrophy, and avoiding the complications of diabetes.

The invention provides a method for combating biofilm, said method comprising contacting a biofilm with a composition comprising effective amounts of one or more biofilm degrading enzymes in combination with antimicrobial agents or antimicrobial essential oils. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In a preferred aspect the invention provides a composition and method for use in the treatment or prevention of a biofilm infection in a subject, particularly in the oral cavity.

The invention relates to a synthetic fusion protein having high antimicrobial activity. In particular, the invention relates to the use of said protein and compositions that include it in the medical field to combat infections caused by pathogenic microorganisms, in particular gram+bacteria, viruses, mycoplasma and fungi.

The present invention is, inter alia, directed towards mannose-binding lectin and compositions comprising mannose-binding lectin for use in treatment or prophylaxis, towards compositions comprising mannose-binding lectin and towards the use of mannose-binding lectin and said compositions. Mannose-binding lectin, or portions thereof are applied locally according to the invention. MBL is binding to a pathogen to prevent it from binding to a host cell by blocking the binding sites of the pathogen. As a result, infection or transmission of disease can be avoided.